This funding suggesting PDLIM2 downregulation may serve as a potential marker for therapy with HIF-1 inhibitors, providing new insights into strategies for precise targeted treatment for lung cancer patients with PDLIM2 downregulation. This evidence concerns the gene HIF1A and lung cancer.